Form 4: Arcellx Director Jill Carroll Granted Stock Options Valued at $63.68 Per Share

Arcellx, Inc. Director Jill Carroll was granted 9,174 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Summary

• Jill Carroll, a Director of Arcellx, Inc. (ACLX), reported the acquisition of stock options.
• The transaction date for the option grant was May 29, 2025.
• A total of 9,174 stock options were acquired.
• The exercise price for these options is $63.68 per share.
• The options are scheduled to vest 100% on the earlier of May 29, 2026, or the next annual meeting of stockholders, contingent on Ms. Carroll's continued service as a Service Provider.
• The expiration date for these stock options is May 29, 2035.
• Following this transaction, Jill Carroll beneficially owns 9,174 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it is a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued commitment and service to the company.

Negatives

• No specific negative aspects are identified within this routine insider transaction filing.

Risks

• The value of the stock options is dependent on the future market price of Arcellx, Inc. common stock exceeding the exercise price of $63.68.
• If the company's stock price does not perform well, the options may expire worthless or have limited intrinsic value.
• Vesting is subject to the reporting person's continuing to be a Service Provider, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options are subject to a vesting schedule, with 100% vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders, provided the director continues to serve the company.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of non-cash compensation to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a common compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Without specific details on Arcellx's compensation philosophy or comparable grants by peer companies (e.g., CRISPR Therapeutics, Bluebird Bio, or Caribou Biosciences), a detailed comparison of the size and terms of this specific grant to industry standards is not feasible from this document alone.

Related Party Transactions

• This filing details a transaction between Arcellx, Inc. and one of its directors, Jill Carroll, which is inherently a related-party transaction in the context of compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation practices can set precedents for executive and director remuneration.

Next Steps

• The stock options will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, subject to continued service.
• The director may choose to exercise the options at any time after vesting and before the expiration date of May 29, 2035, provided the stock price is favorable.

Key Dates

Keywords

Arcellx, ACLX, Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Incentive Plan, Beneficial Ownership